Dec 4, 2025 · Amneal Pharmaceuticals Inc 's Q3 2025 quarter and 12 months market share, relative to the AMRX's competitors. Based on total revenues.

Oct 30, 2025 · “Amneal delivered another strong quarter and updated our 2025 outlook, underscoring the strength of our diversified business and the ongoing evolution of our portfolio.

Find the latest Amneal Pharmaceuticals, Inc. (AMRX) stock quote, history, news and other vital information to help you with your stock trading and investing.

Get the latest Amneal Pharmaceuticals Inc (AMRX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

Oct 30, 2025 · Detailed statistics for Amneal Pharmaceuticals, Inc. (AMRX) stock, including valuation metrics, financial numbers, share information and more.

Amneal Pharmaceuticals posted third-quarter 2025 revenue of $785 million, up 12% year over year, and nudged its full-year outlook higher for adjusted EBITDA, adjusted EPS, and operating cash flow.

3 days ago · Amneal Pharmaceuticals is experiencing a favorable shift in sentiment, driven by a combination of fresh analyst coverage and a significant regulatory milestone.

Information on stock, financials, earnings, subsidiaries, investors, and executives for Amneal Pharmaceuticals. Use the PitchBook Platform to explore the full profile.

May 2, 2025 · “Amneal delivered another strong quarter to start 2025, with broad-based growth across all three segments driven by our team’s outstanding execution.

May 3, 2025 · Analysts have largely embraced the results, with the stock rising 5% premarket to $8.13 despite revenue slightly missing estimates. Price targets of $11–12 reflect optimism about margin …